Development of pituitary adenoma in women with hyperprolactinaemia: clinical, endocrine, and radiological characteristics

ANTONIO E PONTIROLI, LEOPOLDO FALETTI

Abstract

Sixty eight women referred for treatment of hyperprolactinaemia entered a three year follow up study to determine the clinical and endocrine course of the disease and its association with microadenoma of the pituitary. Details recorded before treatment included medical history, gonadotrophin and ovarian hormonal concentrations, and release of prolactin in response to prothrelin (thyrotrophin releasing hormone), benzodiazepine, clomifene, and nomifensine. Sellar tomography was then performed yearly for three years in all women, 54 of them also undergoing computed coronal and sagittal tomography. At baseline evaluation 27 women showed radiological evidence of pituitary adenoma; at the end of the follow up period the number had increased to 41. Amenorrhea, steady and raised serum prolactin concentrations, a low ratio of luteinising hormone to follicle stimulating hormone, a longer duration of disease, and low serum progesterone concentrations were more common in women with a final diagnosis of pituitary adenoma than in those whose sella remained normal. Tests for release of prolactin had yielded abnormal results from the outset in all 41 women with radiological evidence of pituitary adenoma and in about half of those whose sella had remained radiologically normal. Response to medical treatment (metyrapone in 20 patients, bromocriptine in 21) was similar and showed no difference between patients with tumorous and non-tumorous hyperprolactinaemia.

These findings suggest that a large proportion of women with hyperprolactinaemia may harbour a prolactin secreting pituitary adenoma which becomes apparent over a relatively short period. Amenorrhea and steady and raised serum prolactin concentrations are more common in these women. Tests for release of prolactin are of predictive value in identifying women who will develop a pituitary adenoma.
Introduction

Hyperprolactinaemia induces amenorrhoea, galactorrhoea, and infertility and may be due to pituitary adenoma or be a functional (idiopathic) disorder. The natural history of hyperprolactinaemia is not known, and the rate of growth of microadenomas is a subject of controversy. With large adenomas the diagnosis is easy, but this is not so with small prolactin secreting adenomas (microadenomas). Minor changes of the sella turcica detected by sellar tomography have been taken as evidence of microadenoma, but with both sellar tomography and computed tomography (CT) false negative and false positive results may occur. In addition, permanently raised serum prolactin concentrations and the absence of response of prolactin to pharmacological stimuli (protriptyline; thyrotrophin releasing hormone, cimetidine, and benserazide) and to inhibiting stimuli (nomifensine and levodopa-carbidopa) have also reportedly been shown to characterise patients with prolactin secreting pituitary adenomas. The validity of such tests has been questioned, however, since an absent prolactin response may also be observed in patients with a normal radiological appearance of the sella.

With the assumption that patients with hyperprolactinaemia might be harbouring a microadenoma which was still too small to be seen we decided to follow up hyperprolactinaemic women for up to three years and to correlate the final radiological diagnosis with baseline clinical and endocrine findings—namely, details of medical history, pituitary and ovarian hormonal release, and response of prolactin to various stimuli.

Patients and methods

During January 1978 to January 1980, 68 women with hyperprolactinaemia (at least two measurements > 20 μg/l on different days) and various reproductive disorders (amenorrhoea or anovulation with or without galactorrhoea, poly cystic ovarian disease, infertility due to a short luteal phase) entered the study. After exclusion of other endocrine disorders known to induce secondary hyperprolactinaemia (acromegaly, Cushing’s disease, Nelson’s syndrome, primary hypothyroidism, Addison’s disease, chronic renal failure) patients were categorised according to the duration of symptoms or asymptomatic clinical condition. Seven patients had received drugs known to induce hyperprolactinaemia—namely, oestrogens and metoclopramide—but were not excluded. Before beginning any medical treatment all patients underwent a baseline evaluation of serum prolactin concentrations (two or three samples over a three month period) and concentrations of 17β-oestradiol, progesterone, testosterone, follice stimulating hormone (FSH), and luteinising hormone (LH). Sellar tomography was performed in all women and sagittal and coronal CT in 54 of them by means of a third generation IGE 8800 scanner (47 from the outset and seven from one year later). All women underwent a stimulatory test for prolactin release with benserazide (150 mg by mouth). A test with protriptyline (thyrrotrophin releasing hormone; 200 μg intravenously) was performed in 59 patients, with cimetidine (400 mg intravenously) in 37 women, and with nomifensine (200 mg orally) in 28 patients. In 41 women medical treatment was instituted with methergline (20 cases; 8-12 mg/day) or bromocriptine (21 cases; 5-10 mg/day), and after at least 90 days efficacy established as: no result; menses; ovulatory menses; pregnancy.

All patients were followed up for three years by means of sellar tomography or CT, or both, performed yearly. Results of sellar tomography were evaluated by two independent neuroradiologists using the criteria of Vezina and Sutton. Close attention was paid to changes in the sella on repeated examinations (performed under standardised conditions and with the same instrument) rather than to abnormalities seen at a single examination, which might have been due to anatomical variation. With CT a microadenoma was defined as the presence of a hypodense round or oval area within the hypophysis after intravenous injection of contrast media: additional criteria were the displacement of the pituitary stalk or erosions of the bony structures.

In the benserazide, protriptyline, and cimetidine tests a normal prolactin response was defined as doubling of baseline prolactin values; in the nomifensine test a normal response was defined as a mean prolactin concentration at 120, 180, and 240 minutes, at least 33%, lower than baseline. Serum prolactin, FSH, LH, progesterone, 17β-oestradiol, and the intra-assay coefficients of variation vary from 5.8% for progesterone to 7.5% for testosterone, and the between assay coefficients of variation vary from 4.0% for prolactin to 6.6% for progesterone.

Statistical analysis was by Student’s t test for unpaired data and the χ² test.

Results

At baseline evaluation 41 patients were found to have a normal sella, as assessed by sellar tomography or CT, and 27 patients showed evidence of pituitary adenoma. Table I gives the details of the two groups. Prolactin concentrations were found to be steady in each group, but the actual mean values differed significantly (p<0.02). Also the mean LH/FSH ratio and serum progesterone concentration were lower in patients with radiological evidence of pituitary tumour, whereas no significant differences were found in the age of the patients, prevalence of amenorrhoea, duration of the clinical condition, or serum testosterone or 17β-oestradiol concentration. Testing for release of prolactin showed no modification with any agent in patients with evidence of adenoma; however, a preponderance of absent prolactin responses to each test was also found in most patients with a normal radiological appearance of the sella turcica.

At the end of the follow up period there was an impressive increase in the number of patients with radiological evidence of pituitary adenoma as detected by sellar tomography or CT, the final number having reached 41 cases. In two cases in which appearances on sellar tomography had suggested a diagnosis of adenoma CT allowed a final diagnosis of empty sella. Of 15 women with a final diagnosis of adenoma and who had had a normal sella at the outset, 11 had been evaluated by both sellar tomography and CT, six of them simultaneously. In three patients in the latter group CT detected a pituitary adenoma earlier than did sellar tomography, and in the others detection occurred at the same time. Surgical exploration was attempted in eight patients, and in every one a pituitary adenoma was confirmed. Of these eight patients, six had had radiological evidence of adenoma from the outset.

Table II gives the details of the patients at the end of the follow up period. The prevalence of amenorrhoea, duration of the disease, and...
AYS patients with pituitary tumour and 12 with normal sella had LH/FSH ratio greater than 1.0 ($z^2 = 7.24$; $p < 0.02$).

**Results**

Concentration of serum prolactin detected in four patients with normal sella were significantly higher ($z^2 = 6.98$; $p < 0.05$).

**Conclusion**

Seven patients with pituitary tumour and 12 with normal sella had LH/FSH ratio greater than 1.0 ($z^2 = 7.24$; $p < 0.02$).

**Discussion**

In patients with hyperprolactinaemia one of the greatest difficulties is in differentiating between functional hyperprolactinaemia and pituitary adenoma. Attempts to characterise the disease have been based on serial determinations of serum prolactin concentrations and the response of prolactin to stimulating and inhibiting agents, but the validity of these approaches has been questioned. Radiological evaluation of the sella turcica has been greatly improved by high resolution computed tomography, which has replaced traditional invasive diagnostic procedures such as pneumoencephalography and cerebral angiography. A firm criterion for radiological diagnosis of pituitary adenomas, however, is not available.

Unfortunately, the natural history of hyperprolactinaemia is not known. Functional hyperprolactinaemia and pituitary adenoma may represent two different entities or be consecutive stages of the same disorder. Anecdotal evidence indicates that some cases of functional hyperprolactinaemia will be followed by detection of a pituitary prolactin secreting pituitary adenoma. The need for early diagnosis of a prolactin secreting adenoma lies in the fact that cure is obtained only by operation at an early stage, although even then recurrence of hyperprolactinaemia is common. On the other hand, the surgical approach is often refused by patients unless serious local disturbances are present—for example, severe headache or visual field defects.

In our study 68 women with hyperprolactinaemia were followed up for three years; the number with radiological evidence of pituitary adenoma increased from 27 (39.7%) to 41 (60.3%). That so many cases were detected was probably due to the extensive use of combined sellar tomography and CT scans; some patients were initially examined by sellar tomography and later by CT, but in most instances changes were observed with repeated use of the same technique.

At the end of the follow up period there were clear differences between patients with and without radiological evidence of tumour which had not been present at the baseline evaluation. Amenorrhoea, a longer duration of disease, steady and raised prolactin concentrations, a low LH/FSH ratio, and low serum progesterone concentrations had been more common in patients with radiological evidence of adenoma than in patients whose sella remained normal. In addition, in about half of the patients with a normal sella prolactin had shown no response to the various tests. A significant spontaneous decrease of basal prolactin concentrations was observed only in patients with a normal prolactin response to the tests (table II). Interestingly six of the seven patients with iatrogenic hyperprolactinaemia were in the latter group.

In patients with a persistently normal sella and no prolactin response to the various tests the non-responsiveness might be idiopathic. We, however, could not find a normal subject—male or female—who did not respond to each of the tests, which suggests another interpretation—that these patients harbour an extremely slow growing pituitary (micro)adenoma. Cases of pituitary adenomas enlarging over eight years have been reported. Our data therefore indicate that an impaired prolactin response to the tests may precede radiological evidence of pituitary adenoma by one to three years. The tussi used in this study assess dopaminergic and histaminergic control of prolactin secretion, while protirelin acts by a different mechanism. That the result of each of these tests was impaired indicates that the adenoma physically interrupts the connections between the hypothalamus and the pituitary. An augmented dopaminergic tone in the tuberoinfundibular area has been found in animals with hyperprolactinaemia; hence the well known inhibitory effect of dopamine and of dopaminergic drugs on LH release might explain the lower concentrations of LH and consequently the lower LH/FSH ratio in patients with adenoma. Medical treatment was given to 41 patients; pregnancy and ovulation were induced in similar proportions of patients with a normal sella or pituitary adenoma, showing that the response was not influenced by the anatomical condition or baseline prolactin concentration. Our data also indicate that prolactin lowering agents at doses commonly used do not prevent a pituitary adenoma, especially if such doses fail to control hyperprolactinaemia.

In conclusion, patients with hyperprolactinaemia are likely to harbour a pituitary (micro)adenoma; the likelihood increases with the duration of the disease and in the presence of amenorrhoea, steady and raised serum prolactin concentrations, and a low (<1.0) LH/FSH ratio. Stimulatory and inhibiting tests for prolactin release seem to be of adequate predictive value in identifying patients who will develop a pituitary adenoma but do not predict the response to medical treatment.
Methimazole and generation of oxygen radicals by monocytes: potential role in immunosuppression

A P WEETMAN, MARY E HOLT, A K CAMPBELL, R HALL, A M McGR戈

Abstract

A study was conducted investigating the possibility that the immunosuppressive action of methimazole (the active metabolite of the antithyroid drug carbimazole) might be due to an effect on the production of oxygen radicals by monocytes. Techniques comprised measurement of luminol dependent chemoluminescence in monocytes and a spectrophotometric assay for production of hydrogen peroxide.

The results show definite inhibition of formation of oxygen radicals by resting and stimulated monocytes, which may explain the immunosuppressive action of the drug in Graves' disease. The findings also suggest that the formation of oxygen radicals and the initiation of the immune response may be closely related.

References


(Accepted 15 December 1983)